Cyclopharm Limited (ASX:CYC)

Cyclopharm Statistics

Total Valuation

Cyclopharm has a market cap or net worth of AUD 103.36 million. The enterprise value is 98.93 million.

Market Cap	103.36M
Enterprise Value	98.93M

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Cyclopharm has 111.14 million shares outstanding. The number of shares has increased by 16.34% in one year.

Current Share Class	111.14M
Shares Outstanding	111.14M
Shares Change (YoY)	+16.34%
Shares Change (QoQ)	+0.41%
Owned by Insiders (%)	11.28%
Owned by Institutions (%)	22.78%
Float	56.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.36
PB Ratio	2.86
P/TBV Ratio	3.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.40
EV / Sales	3.22
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.89

Financial Position

The company has a current ratio of 3.19, with a Debt / Equity ratio of 0.22.

Current Ratio	3.19
Quick Ratio	1.75
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	-0.56
Interest Coverage	-30.72

Financial Efficiency

Return on equity (ROE) is -31.98% and return on invested capital (ROIC) is -47.45%.

Return on Equity (ROE)	-31.98%
Return on Assets (ROA)	-15.65%
Return on Invested Capital (ROIC)	-47.45%
Return on Capital Employed (ROCE)	-33.73%
Weighted Average Cost of Capital (WACC)	8.95%
Revenue Per Employee	316,710
Profits Per Employee	-137,892
Employee Count	97
Asset Turnover	0.51
Inventory Turnover	0.93

Taxes

Income Tax	-81,621
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.48% in the last 52 weeks. The beta is 0.91, so Cyclopharm's price volatility has been similar to the market average.

Beta (5Y)	0.91
52-Week Price Change	-58.48%
50-Day Moving Average	0.95
200-Day Moving Average	0.95
Relative Strength Index (RSI)	46.15
Average Volume (20 Days)	100,457

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cyclopharm had revenue of AUD 30.72 million and -13.38 million in losses. Loss per share was -0.12.

Revenue	30.72M
Gross Profit	19.29M
Operating Income	-15.02M
Pretax Income	-13.46M
Net Income	-13.38M
EBITDA	-14.07M
EBIT	-15.02M
Loss Per Share	-0.12

Balance Sheet

The company has 12.41 million in cash and 7.98 million in debt, with a net cash position of 4.43 million or 0.04 per share.

Cash & Cash Equivalents	12.41M
Total Debt	7.98M
Net Cash	4.43M
Net Cash Per Share	0.04
Equity (Book Value)	36.10M
Book Value Per Share	0.32
Working Capital	24.90M

Cash Flow

In the last 12 months, operating cash flow was -13.71 million and capital expenditures -647,155, giving a free cash flow of -14.36 million.

Operating Cash Flow	-13.71M
Capital Expenditures	-647,155
Free Cash Flow	-14.36M
FCF Per Share	-0.13

Margins

Gross margin is 62.79%, with operating and profit margins of -48.91% and -43.54%.

Gross Margin	62.79%
Operating Margin	-48.91%
Pretax Margin	-43.80%
Profit Margin	-43.54%
EBITDA Margin	-45.81%
EBIT Margin	-48.91%
FCF Margin	n/a

Dividends & Yields

Cyclopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.34%
Shareholder Yield	-16.34%
Earnings Yield	-12.94%
FCF Yield	-13.89%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 28, 2012. It was a reverse split with a ratio of 0.2.

Last Split Date	May 28, 2012
Split Type	Reverse
Split Ratio	0.2

Scores

Cyclopharm has an Altman Z-Score of 3.82 and a Piotroski F-Score of 1.

Altman Z-Score	3.82
Piotroski F-Score	1